Immix Biopharma (IMMX) Competitors $2.56 +0.15 (+6.02%) As of 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMX vs. NGNE, TNXP, TVRD, DBVT, CADL, SLRN, IMMP, DSGN, CMPS, and ACBShould you be buying Immix Biopharma stock or one of its competitors? The main competitors of Immix Biopharma include Neurogene (NGNE), Tonix Pharmaceuticals (TNXP), Tvardi Therapeutics (TVRD), DBV Technologies (DBVT), Candel Therapeutics (CADL), Acelyrin (SLRN), Prima BioMed (IMMP), Design Therapeutics (DSGN), COMPASS Pathways (CMPS), and Aurora Cannabis (ACB). These companies are all part of the "pharmaceutical products" industry. Immix Biopharma vs. Its Competitors Neurogene Tonix Pharmaceuticals Tvardi Therapeutics DBV Technologies Candel Therapeutics Acelyrin Prima BioMed Design Therapeutics COMPASS Pathways Aurora Cannabis Neurogene (NASDAQ:NGNE) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment. Does the media refer more to NGNE or IMMX? In the previous week, Neurogene had 5 more articles in the media than Immix Biopharma. MarketBeat recorded 6 mentions for Neurogene and 1 mentions for Immix Biopharma. Neurogene's average media sentiment score of 0.15 beat Immix Biopharma's score of 0.00 indicating that Neurogene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immix Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in NGNE or IMMX? 52.4% of Neurogene shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 11.6% of Neurogene shares are owned by insiders. Comparatively, 55.4% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate NGNE or IMMX? Neurogene currently has a consensus target price of $46.17, indicating a potential upside of 130.32%. Immix Biopharma has a consensus target price of $7.00, indicating a potential upside of 173.97%. Given Immix Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Immix Biopharma is more favorable than Neurogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurogene 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Immix Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, NGNE or IMMX? Neurogene has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Which has higher earnings & valuation, NGNE or IMMX? Immix Biopharma has lower revenue, but higher earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurogene$930K307.36-$75.14M-$4.35-4.61Immix BiopharmaN/AN/A-$21.61M-$0.70-3.65 Is NGNE or IMMX more profitable? Neurogene's return on equity of -36.16% beat Immix Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets NeurogeneN/A -36.16% -32.51% Immix Biopharma N/A -130.02%-86.33% SummaryNeurogene beats Immix Biopharma on 8 of the 14 factors compared between the two stocks. Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMX vs. The Competition Export to ExcelMetricImmix BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$71.23M$2.90B$5.50B$9.01BDividend YieldN/A2.64%5.39%4.11%P/E Ratio-3.6521.5027.4220.07Price / SalesN/A282.64398.50109.13Price / CashN/A41.4736.1356.90Price / Book5.327.518.015.70Net Income-$21.61M-$55.05M$3.16B$248.47M7 Day Performance14.06%3.05%2.08%2.92%1 Month Performance21.09%5.80%4.38%5.77%1 Year Performance4.29%6.15%35.81%21.39% Immix Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMXImmix Biopharma3.6888 of 5 stars$2.56+6.0%$7.00+174.0%+23.0%$71.23MN/A-3.659Gap UpNGNENeurogene3.8303 of 5 stars$17.22-3.0%$46.17+168.1%-48.6%$245.56M$930K-3.9690News CoverageTNXPTonix Pharmaceuticals2.5915 of 5 stars$32.79+1.3%$585.00+1,684.1%-52.3%$241.33M$10.09M-0.0250TVRDTvardi TherapeuticsN/A$25.38-1.5%$71.50+181.7%N/A$237.58M$7.14M0.0080High Trading VolumeDBVTDBV Technologies3.7746 of 5 stars$8.56-8.9%$14.75+72.3%+170.1%$234.46M$4.15M-1.7480Analyst RevisionGap UpCADLCandel Therapeutics2.2693 of 5 stars$4.67-1.7%$21.00+349.7%-20.2%$233.97M$120K-3.4960News CoverageAnalyst UpgradeAnalyst RevisionSLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135IMMPPrima BioMed0.8473 of 5 stars$1.52-5.0%$7.00+360.5%-9.6%$221.98M$5.14M0.002,021DSGNDesign Therapeutics0.7494 of 5 stars$3.90+4.3%$4.00+2.6%+15.0%$221.40MN/A-3.9440CMPSCOMPASS Pathways1.9943 of 5 stars$2.35-49.2%$17.00+623.4%-43.3%$219.87MN/A-1.18120High Trading VolumeACBAurora Cannabis0.2918 of 5 stars$3.91-4.2%N/A-1.1%$219.78M$246.72M35.551,073 Related Companies and Tools Related Companies Neurogene Competitors Tonix Pharmaceuticals Competitors Tvardi Therapeutics Competitors DBV Technologies Competitors Candel Therapeutics Competitors Acelyrin Competitors Prima BioMed Competitors Design Therapeutics Competitors COMPASS Pathways Competitors Aurora Cannabis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
